First half performance supports full year confidence |
Underlying performance | GAAP measures | ||||||
(unaudited) | 2025 | vs 2024 | 2025 | vs 2024 | |||
First Half | |||||||
Underlying sales growth (USG) | 3.4% | Turnover | €30.1bn | (3.2)% | |||
Beauty & Wellbeing | 3.7% | Beauty & Wellbeing | €6.5bn | (0.8)% | |||
Personal Care | 4.8% | Personal Care | €6.5bn | (5.9)% | |||
Home Care | 1.3% | Home Care | €5.9bn | (6.7)% | |||
Foods | 2.2% | Foods | €6.6bn | (1.8)% | |||
Ice Cream | 5.9% | Ice Cream | €4.6bn | 0.2% | |||
Underlying operating profit | €5.8bn | (4.8)% | Operating profit | €5.3bn | (10.6)% | ||
Underlying operating margin | 19.3% | (30)bps | Operating margin | 17.6% | (150)bps | ||
Underlying earnings per share | €1.59 | (2.1)% | Diluted earnings per share | €1.42 | (3.7)% | ||
Free cash flow | €1.1bn | €(1.1)bn | Net profit | €3.8bn | (5.1)% | ||
Second Quarter | |||||||
USG | 3.8% | Turnover | €15.4bn | (4.6)% | |||
Quarterly dividend payable in September 2025 | €0.4528 | per share(a) |
Outlook |
First Half Review: Unilever Group |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change |
First Half | €30.1bn | 3.4% | 1.5% | 1.9% | (2.5)% | (4.0)% | (3.2)% |
Second Quarter | €15.4bn | 3.8% | 1.8% | 2.0% | (2.4)% | (5.8)% | (4.6)% |
First Half Review: Unilever Group (continued) |
(unaudited) | UOP | UOP growth | UOM% | Change in UOM | OP | OP growth | OM% | Change in OM |
First Half | €5.8bn | (4.8)% | 19.3% | (30)bps | €5.3bn | (10.6)% | 17.6% | (150)bps |
Conference Call |
Upcoming Events |
Date | Events |
9 September 2025 | The Magnum Ice Cream Company Capital Markets Day |
23 October 2025 | Third quarter trading statement |
First Half Review: Business Groups |
First Half 2025 | Second Quarter 2025 | |||||||||
(unaudited) | Turnover | USG | UVG | UPG | UOM% | Change in UOM | Turnover | USG | UVG | UPG |
Unilever | €30.1bn | 3.4% | 1.5% | 1.9% | 19.3% | (30)bps | €15.4bn | 3.8% | 1.8% | 2.0% |
Beauty & Wellbeing | €6.5bn | 3.7% | 1.7% | 2.0% | 19.4% | (60)bps | €3.2bn | 3.4% | 1.0% | 2.4% |
Personal Care | €6.5bn | 4.8% | 1.4% | 3.3% | 22.1% | (90)bps | €3.3bn | 4.5% | 0.2% | 4.3% |
Home Care | €5.9bn | 1.3% | 1.1% | 0.2% | 15.5% | (80)bps | €2.9bn | 1.8% | 1.3% | 0.4% |
Foods | €6.6bn | 2.2% | 0.3% | 1.9% | 23.3% | 100bps | €3.2bn | 2.8% | 1.7% | 1.0% |
Ice Cream | €4.6bn | 5.9% | 3.8% | 2.0% | 14.2% | (40)bps | €2.8bn | 7.1% | 5.0% | 1.9% |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €6.5bn | 3.7% | 1.7% | 2.0% | (1.0)% | (3.4)% | (0.8)% | 19.4% | (60)bps |
Second Quarter | €3.2bn | 3.4% | 1.0% | 2.4% | (0.9)% | (6.1)% | (3.7)% |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €6.5bn | 4.8% | 1.4% | 3.3% | (5.8)% | (4.6)% | (5.9)% | 22.1% | (90)bps |
Second Quarter | €3.3bn | 4.5% | 0.2% | 4.3% | (4.6)% | (6.3)% | (6.6)% |
First Half Review: Business Groups (continued) |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €5.9bn | 1.3% | 1.1% | 0.2% | (2.7)% | (5.4)% | (6.7)% | 15.5% | (80)bps |
Second Quarter | €2.9bn | 1.8% | 1.3% | 0.4% | (2.9)% | (6.8)% | (8.0)% |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €6.6bn | 2.2% | 0.3% | 1.9% | (0.7)% | (3.2)% | (1.8)% | 23.3% | 100bps |
Second Quarter | €3.2bn | 2.8% | 1.7% | 1.0% | (0.8)% | (5.0)% | (3.1)% |
First Half Review: Business Groups (continued) |
(unaudited) | Turnover | USG | UVG | UPG | A&D | Currency | Turnover change | UOM% | Change in UOM |
First Half | €4.6bn | 5.9% | 3.8% | 2.0% | (2.3)% | (3.1)% | 0.2% | 14.2% | (40)bps |
Second Quarter | €2.8bn | 7.1% | 5.0% | 1.9% | (2.7)% | (4.8)% | (0.8)% |
First Half Review: Geographical Areas |
First Half 2025 | Second Quarter 2025 | |||||||
(unaudited) | Turnover | USG | UVG | UPG | Turnover | USG | UVG | UPG |
Unilever | €30.1bn | 3.4% | 1.5% | 1.9% | €15.4bn | 3.8% | 1.8% | 2.0% |
Asia Pacific Africa | €12.8bn | 3.5% | 1.9% | 1.6% | €6.3bn | 5.1% | 3.1% | 1.9% |
The Americas | €10.9bn | 3.4% | 0.4% | 3.0% | €5.5bn | 2.6% | (0.3)% | 3.0% |
Europe | €6.4bn | 3.4% | 2.8% | 0.6% | €3.6bn | 3.5% | 2.6% | 0.8% |
First Half 2025 | Second Quarter 2025 | |||||||
(unaudited) | Turnover | USG | UVG | UPG | Turnover | USG | UVG | UPG |
Emerging markets | €17.0bn | 2.8% | 0.2% | 2.6% | €8.5bn | 3.6% | 0.5% | 3.1% |
Developed markets | €13.1bn | 4.3% | 3.4% | 0.9% | €6.9bn | 4.1% | 3.4% | 0.7% |
North America | €6.8bn | 5.4% | 3.7% | 1.6% | €3.5bn | 4.6% | 3.4% | 1.1% |
Latin America | €4.1bn | 0.5% | (4.6)% | 5.3% | €2.0bn | (0.4)% | (6.1)% | 6.0% |
Additional commentary on the financial statements - First Half |
Non-GAAP measures |
Half year average rate in 2025 | Half year average rate in 2024 | |
Brazilian real (€1 = BRL) | 6.281 | 5.478 |
Chinese yuan (€1 = CNY) | 7.895 | 7.732 |
Indian rupee (€1 = INR) | 93.749 | 90.004 |
Indonesia rupiah (€1 = IDR) | 17,874 | 17,180 |
Mexican peso (€1 = MXN) | 21.788 | 18.445 |
Philippine peso (€1 = PHP) | 62.192 | 61.459 |
Turkish lira (€1 = TRY) | 40.649 | 34.187 |
UK pound sterling (€1 = GBP) | 0.842 | 0.855 |
US dollar (€1 = US$) | 1.088 | 1.082 |
Non-GAAP measures (continued) |
(unaudited) | Beauty & Wellbeing | Personal Care | Home Care | Foods | Ice Cream | Total |
Second Quarter | ||||||
Turnover (€ million) | ||||||
2024 | 3,343 | 3,531 | 3,113 | 3,289 | 2,815 | 16,091 |
2025 | 3,219 | 3,296 | 2,865 | 3,187 | 2,792 | 15,359 |
Turnover growth (%) | (3.7) | (6.6) | (8.0) | (3.1) | (0.8) | (4.6) |
Effect of acquisitions (%) | 0.4 | 0.8 | – | – | – | 0.2 |
Effect of disposals (%) | (1.2) | (5.3) | (2.9) | (0.8) | (2.7) | (2.6) |
Effect of currency-related items (%), of which: | (6.1) | (6.3) | (6.8) | (5.0) | (4.8) | (5.8) |
Exchange rates changes (%) | (6.3) | (7.0) | (7.3) | (5.4) | (5.6) | (6.3) |
Extreme price growth in hyperinflationary markets* (%) | 0.3 | 0.7 | 0.5 | 0.5 | 0.8 | 0.6 |
Underlying sales growth (%) | 3.4 | 4.5 | 1.8 | 2.8 | 7.1 | 3.8 |
First Half | ||||||
Turnover (€ million) | ||||||
2024 | 6,539 | 6,953 | 6,328 | 6,687 | 4,610 | 31,117 |
2025 | 6,489 | 6,545 | 5,904 | 6,568 | 4,621 | 30,127 |
Turnover growth (%) | (0.8) | (5.9) | (6.7) | (1.8) | 0.2 | (3.2) |
Effect of acquisitions (%) | 0.3 | 0.4 | – | – | – | 0.2 |
Effect of disposals (%) | (1.3) | (6.2) | (2.7) | (0.7) | (2.3) | (2.7) |
Effect of currency-related items (%), of which: | (3.4) | (4.6) | (5.4) | (3.2) | (3.1) | (4.0) |
Exchange rates changes (%) | (3.8) | (5.2) | (5.8) | (3.7) | (4.1) | (4.6) |
Extreme price growth in hyperinflationary markets* (%) | 0.5 | 0.6 | 0.5 | 0.5 | 1.1 | 0.6 |
Underlying sales growth (%) | 3.7 | 4.8 | 1.3 | 2.2 | 5.9 | 3.4 |
(unaudited) | Asia Pacific Africa | The Americas | Europe | Total |
Second Quarter | ||||
Turnover (€ million) | ||||
2024 | 6,732 | 5,924 | 3,435 | 16,091 |
2025 | 6,335 | 5,488 | 3,536 | 15,359 |
Turnover growth (%) | (5.9) | (7.4) | 2.9 | (4.6) |
Effect of acquisitions (%) | 0.2 | – | 0.8 | 0.2 |
Effect of disposals (%) | (4.3) | (1.3) | (1.6) | (2.6) |
Effect of currency-related items (%), of which: | (6.6) | (8.5) | 0.3 | (5.8) |
Exchange rates changes (%) | (7.3) | (9.1) | 0.3 | (6.3) |
Extreme price growth in hyperinflationary markets* (%) | 0.7 | 0.7 | – | 0.6 |
Underlying sales growth (%) | 5.1 | 2.6 | 3.5 | 3.8 |
First Half | ||||
Turnover (€ million) | ||||
2024 | 13,370 | 11,463 | 6,284 | 31,117 |
2025 | 12,795 | 10,903 | 6,429 | 30,127 |
Turnover growth (%) | (4.3) | (4.9) | 2.3 | (3.2) |
Effect of acquisitions (%) | 0.1 | 0.1 | 0.4 | 0.2 |
Effect of disposals (%) | (3.9) | (1.8) | (1.8) | (2.7) |
Effect of currency-related items (%), of which: | (3.9) | (6.4) | 0.4 | (4.0) |
Exchange rates changes (%) | (4.6) | (7.3) | 0.4 | (4.6) |
Extreme price growth in hyperinflationary markets* (%) | 0.7 | 0.9 | – | 0.6 |
Underlying sales growth (%) | 3.5 | 3.4 | 3.4 | 3.4 |
Non-GAAP measures (continued) |
Non-GAAP measures (continued) |
€ million | First Half | |
(unaudited) | 2025 | 2024 |
Non-underlying items within operating profit before tax | (491) | (152) |
Acquisition and disposal-related costs(a) | (239) | (58) |
Gain on disposal of group companies(b) | 47 | 155 |
Restructuring costs(c) | (239) | (248) |
Impairments(d) | (51) | – |
Other | (9) | (1) |
Tax on non-underlying items within operating profit | 101 | (51) |
Non-underlying items within operating profit after tax | (390) | (203) |
Non-underlying items not in operating profit but within net profit before tax | (17) | (160) |
Interest related to the UK tax audit of intangible income and centralised services | – | (3) |
Net monetary loss arising from hyperinflationary economies | (17) | (157) |
Tax impact of non-underlying items not in operating profit but within net profit, including non-underlying tax items | (10) | (4) |
Non-underlying items not in operating profit but within net profit after tax | (27) | (164) |
Non-underlying items after tax | (417) | (367) |
Attributable to: | ||
Non-controlling interests | (9) | (1) |
Shareholders’ equity | (408) | (366) |
€ million | First Half | |
(unaudited) | 2025 | 2024 |
Operating profit | 5,315 | 5,948 |
Non-underlying items within operating profit | 491 | 152 |
Underlying operating profit | 5,806 | 6,100 |
Turnover | 30,127 | 31,117 |
Operating margin (%) | 17.6 | 19.1 |
Underlying operating margin (%) | 19.3 | 19.6 |
Non-GAAP measures (continued) |
€ million | First Half | |
(unaudited) | 2025 | 2024 |
Taxation | 1,282 | 1,550 |
Tax impact of: | ||
Non-underlying items within operating profit(a) | 101 | (51) |
Non-underlying items not in operating profit but within net profit(a) | (10) | (4) |
Taxation before tax impact of non-underlying items | 1,373 | 1,495 |
Profit before taxation | 5,093 | 5,566 |
Share of net (profit)/loss of joint ventures and associates | (146) | (138) |
Profit before tax excluding share of net profit/(loss) of joint ventures and associates | 4,947 | 5,428 |
Non-underlying items within operating profit before tax(a) | 491 | 152 |
Non-underlying items not in operating profit but within net profit before tax | 17 | 160 |
Profit before tax excluding non-underlying items before tax and share of net profit/ (loss) of joint ventures and associates | 5,455 | 5,740 |
Effective tax rate (%) | 25.9 | 28.6 |
Underlying effective tax rate (%) | 25.2 | 26.0 |
€ million | First Half | |
(unaudited) | 2025 | 2024 |
Net profit | 3,811 | 4,016 |
Non-controlling interest | (299) | (315) |
Net profit attributable to shareholders’ equity - used for basic and diluted earnings per share | 3,512 | 3,701 |
Post-tax impact of non-underlying items attributable to shareholders’ equity | 408 | 366 |
Underlying profit attributable to shareholders’ equity - used for basic and diluted earnings per share | 3,920 | 4,067 |
Adjusted average number of shares (millions of share units) | 2,473.2 | 2,511.0 |
Diluted EPS (€) | 1.42 | 1.47 |
Underlying EPS – diluted (€) | 1.59 | 1.62 |
Non-GAAP measures (continued) |
€ million | As at 30 June 2025 | As at 31 December 2024 | As at 30 June 2024 |
(unaudited) | |||
Total financial liabilities | (32,025) | (32,053) | (31,654) |
Current financial liabilities | (7,155) | (6,987) | (7,643) |
Non-current financial liabilities | (24,870) | (25,066) | (24,011) |
Cash and cash equivalents as per balance sheet | 4,344 | 6,136 | 4,970 |
Cash and cash equivalents as per cash flow statement | 4,268 | 5,950 | 4,854 |
Add: bank overdrafts deducted therein | 70 | 180 | 116 |
Less: cash and cash equivalents held for sale | 6 | 6 | – |
Other current financial assets | 1,123 | 1,330 | 1,445 |
Non-current financial asset derivatives that relate to financial liabilities | 203 | 68 | 39 |
Net debt | (26,355) | (24,519) | (25,200) |
€ million | First Half | |
(unaudited) | 2025 | 2024 |
Net profit | 3,811 | 4,016 |
Net finance costs | 320 | 358 |
Net monetary loss arising from hyperinflationary economies | 17 | 157 |
Share of net profit of joint ventures and associates | (146) | (138) |
Other loss/(income) from non-current investments and associates | 31 | 5 |
Taxation | 1,282 | 1,550 |
Operating profit | 5,315 | 5,948 |
Depreciation and amortisation | 795 | 794 |
Earnings before interest, taxes, depreciation and amortisation (EBITDA) | 6,110 | 6,742 |
Non-underlying items within operating profit | 491 | 152 |
Underlying earnings before interest, taxes, depreciation and amortisation (UEBITDA) | 6,601 | 6,894 |
Non-GAAP measures (continued) |
€ million | First Half | |
(unaudited) | 2025 | 2024 |
Cash flow from operating activities | 3,529 | 4,679 |
Income tax paid | (1,242) | (1,315) |
Net capital expenditure | (633) | (710) |
Net interest paid | (526) | (502) |
Free cash flow | 1,128 | 2,152 |
Net cash flow used in investing activities | (648) | (392) |
Net cash flow used in financing activities | (2,941) | (2,154) |
Other Information |
Principal Risk Factors |
Cautionary Statement |
Directors' Responsibility Statement |
Enquiries |
Media: Media Relations Team | Investors: Investor Relations Team | |||
UK | +44 77 4249 0136 | press-office.london@unilever.com | investor.relations@unilever.com | |
or | +44 77 7990 9683 | jonathan.sibun@teneo.com | ||
NL | +31 61 500 8293 | fleur-van.bruggen@unilever.com |
Consolidated income statement |
€ million | First Half | ||
(unaudited) | 2025 | 2024 | Change |
Turnover | (3.2)% | ||
Operating profit | (10.6)% | ||
Net finance costs | ( | ( | |
Pensions and similar obligations | |||
Finance income | |||
Finance costs | ( | ( | |
Net monetary loss arising from hyperinflationary economies | ( | ( | |
Share of net profit of joint ventures and associates | |||
Other loss from non-current investments and associates | ( | ( | |
Profit before taxation | (8.5)% | ||
Taxation | ( | ( | |
Net profit | (5.1)% | ||
Attributable to: | |||
Non-controlling interests | |||
Shareholders’ equity | (5.1)% |
Earnings per share | |||
Basic earnings per share (euros) | (3.7)% | ||
Diluted earnings per share (euros) | (3.7)% |
Consolidated statement of comprehensive income |
€ million | First Half | |
(unaudited) | 2025 | 2024 |
Net profit | ||
Other comprehensive income | ||
Items that will not be reclassified to profit or loss, net of tax: | ||
(Losses)/gains on equity instruments measured at fair value through other comprehensive income | ( | |
Remeasurement of defined benefit pension plans | ( | |
Items that may be reclassified subsequently to profit or loss, net of tax: | ||
(Losses)/gains on cash flow hedges | ( | |
Currency retranslation gains/(losses) | ( | |
Total comprehensive income | ||
Attributable to: | ||
Non-controlling interests | ||
Shareholders’ equity |
Consolidated statement of changes in equity |
(unaudited) | ||||||||
€ million | Called up share capital | Share premium account | Unification reserve | Other reserves | Retained profit | Total | Non- controlling interest | Total equity |
First half - 2025 | ||||||||
1 January 2025 | ( | ( | ||||||
Profit or loss for the period | – | – | – | – | ||||
Other comprehensive income, net of tax: | ||||||||
Equity instruments (losses)/gains | – | – | – | ( | – | ( | – | ( |
Cash flow hedges (losses)gains | – | – | – | ( | – | ( | ( | ( |
Remeasurements of defined benefit pension plans | – | – | – | – | ( | ( | ( | ( |
Currency retranslation (losses)/ gains(a) | – | – | – | ( | ( | ( | ( | ( |
Total comprehensive income | – | – | – | ( | ||||
Dividends on ordinary capital | – | – | – | – | ( | ( | – | ( |
Repurchase of shares(b) | – | – | – | ( | – | ( | – | ( |
Movements in treasury shares(c) | – | – | – | ( | ( | – | ( | |
Share-based payment credit(d) | – | – | – | – | – | |||
Dividends paid to non-controlling interests | – | – | – | – | – | – | ( | ( |
Hedging loss/(gain) transferred to non- financial assets | – | – | – | ( | – | ( | ( | |
Other movements in equity(e) | – | – | – | ( | ( | ( | ||
30 June 2025 | ( | ( | ||||||
First half - 2024 | ||||||||
1 January 2024 | ( | ( | ||||||
Profit or loss for the period | – | – | – | – | ||||
Other comprehensive income, net of tax: | ||||||||
Equity instruments gains/(losses) | – | – | – | – | – | |||
Cash flow hedges gains/(losses) | – | – | – | – | – | |||
Remeasurements of defined benefit pension plans | – | – | – | – | ||||
Currency retranslation gains/ (losses)(a) | – | – | – | |||||
Total comprehensive income | – | – | – | |||||
Dividends on ordinary capital | – | – | – | – | ( | ( | – | ( |
Repurchase of shares(b) | – | – | – | ( | – | ( | – | ( |
Movements in treasury shares(c) | – | – | – | ( | ( | – | ( | |
Share-based payment credit(d) | – | – | – | – | – | |||
Dividends paid to non-controlling interests | – | – | – | – | – | – | ( | ( |
Hedging loss/(gain) transferred to non- financial assets | – | – | – | – | – | |||
Other movements in equity(f) | – | – | – | ( | ( | ( | ||
30 June 2024 | ( | ( |
Consolidated balance sheet |
(unaudited) | |||
€ million | As at 30 June 2025 | As at 31 December 2024 | As at 30 June 2024 |
Non-current assets | |||
Goodwill | |||
Intangible assets | |||
Property, plant and equipment | |||
Pension asset for funded schemes in surplus | |||
Deferred tax assets | |||
Financial assets | |||
Other non-current assets | |||
Current assets | |||
Inventories | |||
Trade and other current receivables | |||
Current tax assets | |||
Cash and cash equivalents | |||
Other financial assets | |||
Assets held for sale | |||
Total assets | |||
Current liabilities | |||
Financial liabilities | |||
Trade payables and other current liabilities | |||
Current tax liabilities | |||
Provisions | |||
Liabilities held for sale | |||
Non-current liabilities | |||
Financial liabilities | |||
Non-current tax liabilities | |||
Pensions and post-retirement healthcare liabilities: | |||
Funded schemes in deficit | |||
Unfunded schemes | |||
Provisions | |||
Deferred tax liabilities | |||
Other non-current liabilities | |||
Total liabilities | |||
Equity | |||
Shareholders’ equity | |||
Non-controlling interests | |||
Total equity | |||
Total liabilities and equity |
Consolidated cash flow statement |
(unaudited) | First Half | |
€ million | 2025 | 2024 |
Net profit | ||
Taxation | ||
Share of net (profit)/loss of joint ventures/associates and other (income)/loss from non-current investments and associates | ( | ( |
Net monetary loss/(gain) arising from hyperinflationary economies | ||
Net finance costs | ||
Operating profit | ||
Depreciation, amortisation and impairment | ||
Changes in working capital | ( | ( |
Inventories | ( | ( |
Trade and other receivables | ( | ( |
Trade payables and other liabilities | ||
Pensions and similar obligations less payments | ||
Provisions less payments | ( | |
Elimination of (profits)/losses on disposals | ( | ( |
Non-cash charge for share-based compensation | ||
Other adjustments | ( | |
Cash flow from operating activities | ||
Income tax paid | ( | ( |
Net cash flow from operating activities | ||
Interest received | ||
Purchase of intangible assets | ( | ( |
Purchase of property, plant and equipment | ( | ( |
Disposal of property, plant and equipment | ||
Acquisition of businesses and investments in joint ventures and associates | ( | ( |
Disposal of businesses, joint ventures and associates | ||
Acquisition of other non-current investments | ( | ( |
Disposal of other non-current investments | ||
Dividends from joint ventures, associates and other non-current investments | ||
Sale/(purchase) of financial assets | ||
Net cash flow used in investing activities | ( | ( |
Dividends paid on ordinary share capital | ( | ( |
Interest paid | ( | ( |
Net change in short-term borrowings | ||
Additional financial liabilities | ||
Repayment of financial liabilities | ( | ( |
Capital element of lease rental payments | ( | ( |
Repurchase of shares | ( | ( |
Other financing activities | ( | ( |
Net cash flow used in financing activities | ( | ( |
Net (decrease)/increase in cash and cash equivalents | ( | |
Cash and cash equivalents at the beginning of the period | ||
Effect of foreign exchange rate changes | ( | ( |
Cash and cash equivalents at the end of the period |
Notes to the condensed consolidated financial statements |
1.Accounting information and policies |
Notes to the condensed consolidated financial statements |
2.Segment information - Business Groups |
Second Quarter | Beauty & Wellbeing | Personal Care | Home Care | Foods | Ice Cream | Total |
Turnover (€ million) | ||||||
2024 | ||||||
2025 | ||||||
Change (%) | ( | ( | ( | ( | ( | ( |
First Half | Beauty & Wellbeing | Personal Care | Home Care | Foods | Ice Cream | Total |
Turnover (€ million) | ||||||
2024 | ||||||
2025 | ||||||
Change (%) | ( | ( | ( | ( | ( | |
Operating profit (€ million) | ||||||
2024 | ||||||
2025 | ||||||
Underlying operating profit (€ million) | ||||||
2024 | ||||||
2025 |
3.Segment information - Geographical area |
Second Quarter | Asia Pacific Africa | The Americas | Europe | Total |
Turnover (€ million) | ||||
2024 | ||||
2025 | ||||
Change (%) | ( | ( | ( |
First Half | Asia Pacific Africa | The Americas | Europe | Total |
Turnover (€ million) | ||||
2024 | ||||
2025 | ||||
Change (%) | ( | ( | ( |
Notes to the condensed consolidated financial statements |
4.Taxation |
5.Earnings per share |
First Half | ||
2025 | 2024 | |
EPS – Basic | ||
Net profit attributable to shareholders’ equity (€ million) | ||
Average number of shares (millions of share units) | ||
EPS – basic (€) | ||
EPS – Diluted | ||
Net profit attributable to shareholders’ equity (€ million) | ||
Adjusted average number of shares (millions of share units) | ||
EPS – diluted (€) |
Millions | |
Number of shares at 31 December 2024 (net of treasury shares) | |
Shares repurchased under the share buyback programme | ( |
Net movements in shares under incentive schemes | |
Number of shares at 30 June 2025 (net of treasury shares) |
Notes to the condensed consolidated financial statements |
6.Acquisitions and disposals |
Deal completion date | Acquired/disposed business |
1 April 2025 | Acquired lip balms, body washes, and handwashes. The acquisition marks another step in the optimisation of Unilever’s portfolio towards premium and high growth spaces. |
1 April 2025 | Sold Conimex brand to Paulig Group. Conimex is an authentic Southeast Asian cuisine brand with an extensive line of spices, sauces, and meal kits. |
1 April 2025 | Acquired the remaining ownership to |
21 April 2025 | HUL acquired The transaction is part of the Beauty & Wellbeing portfolio journey towards evolving and higher growth demand spaces. |
7.Share buyback |
Notes to the condensed consolidated financial statements |
8.Financial instruments |
30 June 2025 | 31 December 2024 | 30 June 2024 | |||||||
Current | Non- current | Total | Current | Non- current | Total | Current | Non- current | Total | |
Cash and cash equivalents | |||||||||
Cash at bank and in hand | |||||||||
Short-term deposits(a) | |||||||||
Other cash equivalents(b) | |||||||||
Other financial assets | |||||||||
Financial assets at amortised cost(c) | |||||||||
Financial assets at fair value through other comprehensive income(d) | |||||||||
Financial assets at fair value through profit or loss: | |||||||||
Derivatives | |||||||||
Other(e) | |||||||||
Total financial assets(f) |
Notes to the condensed consolidated financial statements |
8.Financial instruments (continued) |
€ million | Fair value | Carrying amount | ||||
As at 30 June 2025 | As at 31 December 2024 | As at 30 June 2024 | As at 30 June 2025 | As at 31 December 2024 | As at 30 June 2024 | |
Financial assets | ||||||
Cash and cash equivalents | ||||||
Financial assets at amortised cost | ||||||
Financial assets at fair value through other comprehensive income | ||||||
Financial assets at fair value through profit and loss: | ||||||
Derivatives | ||||||
Other | ||||||
Financial liabilities | ||||||
Bank loans and overdrafts | ( | ( | ( | ( | ( | ( |
Bonds and other loans | ( | ( | ( | ( | ( | ( |
Lease liabilities | ( | ( | ( | ( | ( | ( |
Derivatives | ( | ( | ( | ( | ( | ( |
Other financial liabilities | ( | ( | ( | ( | ( | ( |
( | ( | ( | ( | ( | ( |
€ million | As at 30 June 2025 | As at 31 December 2024 | As at 30 June 2024 | ||||||
Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 | Level 1 | Level 2 | Level 3 | |
Assets at fair value | |||||||||
Financial assets at fair value through other comprehensive income | |||||||||
Financial assets at fair value through profit or loss: | |||||||||
Derivatives(a) | |||||||||
Other | |||||||||
Liabilities at fair value | |||||||||
Derivatives(b) | ( | ( | ( | ||||||
Contingent consideration | ( | ( | ( |
Notes to the condensed consolidated financial statements |
9.Dividends |
Per Unilever PLC ordinary share (traded on the London Stock Exchange): | £ |
Per Unilever PLC ordinary share (traded on Euronext in Amsterdam): | € |
Per Unilever PLC American Depositary Receipt: | US$ |
Announcement Date | Ex-dividend Date for Ordinary Shares | Ex-dividend Date for ADRs | Record Date | Last Date for DRIP Election | Payment Date | |
Q2 2025 Dividend | 31 July 2025 | 14 August 2025 | 15 August 2025 | 15 August 2025 | 21 August 2025 | 12 September 2025 |
Q3 2025 Dividend | 23 October 2025 | 06 November 2025 | 07 November 2025 | 07 November 2025 | 14 November 2025 | 05 December 2025 |
10.Events after the balance sheet date |